Article
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Haematologica - 1 Oct 2019
Ramakrishnan Vijay G, Miller Kevin C, Macon Elaine P, Kimlinger Teresa K, Haug Jessica, Kumar Sanjay, Gonsalves Wilson I, Rajkumar S Vincent, Kumar Shaji K
Abstract excerpt
Despite recent advances in the treatment of multiple myeloma, patients with this disease still inevitably relapse and become refractory to existing therapies. Mutations in K-RAS, N-RAS and B-RAF are common in multiple myeloma, affecting 50% of patients at diagnosis and >70% at relapse. However, targeting mutated RAS/RAF via MEK inhibition is merely cytostatic in myeloma and largely ineffective in the clinic. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.